A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease

Trial Profile

A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs OMS 721 (Primary)
  • Indications IgA nephropathy; Lupus nephritis
  • Focus Adverse reactions
  • Sponsors Omeros Corporation
  • Most Recent Events

    • 06 Nov 2017 Results presented in an Omeros Corporation media release.
    • 06 Nov 2017 According to an Omeros Corporation media release, extended follow-up data were presented on November 4, 2017 at the American Society of Nephrology (ASN) Meeting.
    • 14 Aug 2017 According to an Omeros Corporation media release, data from this trial has been presented at the 54th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top